Caplin Point Laboratories Limited
BSE: CAPPL
BSE
1,446.00
54.85 (3.94%)
Prev Close
1391.15
Open Price
1400.5
Volume
27,832
Today Low / High
1393 / 1468.9
52 WK Low / High
180 / 1468.9
Range
1,374 - 1,518
The stock is currently available for trading on the Bombay Stock Exchange (BSE). Its price is 1446, reflecting a change of 54.85 (3.9428%). The expected target range on the BSE is 1,374 - 1,518. The stock is showing an upward trend on the BSE, making it an appealing option for investors looking for growth in their portfolio.
Caplin Point Laboratories Limited Graph
Caplin Point Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Caplin Point Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,446.00, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,446.00 | 1,460.46 | 1,314.41 - 1,606.51 |
| 1,474.92 | 1,179.94 - 1,769.90 | ||
| 1,489.38 | 1,042.57 - 1,936.19 | ||
| Bearish Scenario | 1,446.00 | 1,431.54 | 1,288.39 - 1,574.69 |
| 1,417.08 | 1,133.66 - 1,700.50 | ||
| 1,402.62 | 981.83 - 1,823.41 |
Overview of Caplin Point Laboratories Limited
ISIN
INE475E01026
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
18,900
Market Cap
109,379,484,462
Last Dividend
4.5
Official Website
IPO Date
DCF Diff
N/A
DCF
0
Financial Ratios Every Investor Needs
Stock Dividend of CAPPL
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2023-09-14 | September 14, 23 | 2.5 | 2.5 | 2023-09-14 | 2023-10-21 | |
| 2023-06-09 | June 09, 23 | 2 | 2 | 2023-06-09 | 2023-08-26 | |
| 2022-09-21 | September 21, 22 | 2 | 2 | 2022-09-22 | 2022-10-29 | |
| 2022-05-23 | May 23, 22 | 2 | 2 | 2022-05-24 | 2022-06-11 | |
| 2021-09-20 | September 20, 21 | 1.5 | 1.5 | 2021-09-21 | 2021-10-28 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-31 | 1,453.82 Cr | 895.52 Cr | 558.30 Cr | 0.3840 | 63.19 Cr | 0.00 Cr | 388.83 Cr | 376.26 Cr | 49.18 | 433.82 Cr | 0.2588 |
| 2022-03-31 | 1,263.01 Cr | 761.19 Cr | 501.82 Cr | 0.3973 | 59.27 Cr | 0.00 Cr | 346.44 Cr | 299.84 Cr | 39.26 | 393.34 Cr | 0.2374 |
| 2021-03-31 | 1,048.26 Cr | 641.98 Cr | 406.28 Cr | 0.3876 | 53.69 Cr | 0.00 Cr | 283.82 Cr | 242.27 Cr | 31.74 | 320.79 Cr | 0.2311 |
| 2020-03-31 | 844.52 Cr | 542.57 Cr | 301.95 Cr | 0.3575 | 53.01 Cr | 0.00 Cr | 210.77 Cr | 215.01 Cr | 28.20 | 242.39 Cr | 0.2546 |
| 2019-03-31 | 632.89 Cr | 388.37 Cr | 244.52 Cr | 0.3864 | 28.19 Cr | 0.00 Cr | 192.75 Cr | 176.57 Cr | 23.23 | 216.18 Cr | 0.2790 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-31 | 179.93 Cr | 2,205.54 Cr | 293.75 Cr | 1,880.4800 Cr | 5.48 Cr | -174.45 Cr | 288.22 Cr | 533.74 Cr | 22.53 Cr | 0.00 Cr | 70.91 Cr | 268.0000 Cr |
| 2022-03-31 | 153.02 Cr | 1,758.11 Cr | 242.12 Cr | 1,483.9300 Cr | 2.13 Cr | -150.89 Cr | 227.31 Cr | 355.72 Cr | 5.49 Cr | 0.00 Cr | 62.09 Cr | 207.6800 Cr |
| 2021-03-31 | 234.19 Cr | 1,383.42 Cr | 173.05 Cr | 1,185.8216 Cr | 18.39 Cr | -215.80 Cr | 179.00 Cr | 317.40 Cr | 2.61 Cr | 0.00 Cr | 0.66 Cr | 142.8535 Cr |
| 2020-03-31 | 52.59 Cr | 1,137.78 Cr | 175.99 Cr | 947.9142 Cr | 38.61 Cr | -13.98 Cr | 238.23 Cr | 290.17 Cr | 2.66 Cr | 1.28 Cr | 0.56 Cr | 144.3247 Cr |
| 2019-03-31 | 51.65 Cr | 747.44 Cr | 110.79 Cr | 632.9094 Cr | 0.54 Cr | -51.11 Cr | 37.45 Cr | 237.78 Cr | 2.33 Cr | 0.00 Cr | 7.64 Cr | 86.1115 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-31 | 297.4100 Cr | -244.4000 Cr | -27.3900 Cr | 103.9400 Cr | 25.6200 Cr | 25.6200 Cr | -193.4700 Cr | 376.2600 Cr | 0.0000 Cr | -30.3200 Cr | -60.9000 Cr |
| 2022-03-31 | 355.6500 Cr | -290.5400 Cr | -40.0100 Cr | 264.4700 Cr | 25.1000 Cr | 25.1000 Cr | -91.1800 Cr | 299.8400 Cr | 0.0000 Cr | -22.6900 Cr | -48.3100 Cr |
| 2021-03-31 | 277.7795 Cr | -18.9075 Cr | -22.4368 Cr | 207.2964 Cr | 236.4352 Cr | 236.4352 Cr | -70.4831 Cr | 242.2662 Cr | 0.0000 Cr | -3.0257 Cr | 59.2298 Cr |
| 2020-03-31 | 48.6539 Cr | -58.7526 Cr | 80.0361 Cr | -28.0842 Cr | 69.9374 Cr | 69.9374 Cr | -76.7381 Cr | 215.0080 Cr | 0.0000 Cr | -32.5263 Cr | -7.0315 Cr |
| 2019-03-31 | 84.7164 Cr | -101.8069 Cr | 89.8496 Cr | 19.5349 Cr | 72.7591 Cr | 72.7591 Cr | -65.1815 Cr | 176.5670 Cr | 0.0000 Cr | -15.1207 Cr | -8.9896 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | 435.50 Cr | 240.68 Cr | 194.82 Cr | 0.4473 | 128.38 Cr | 117.20 Cr | 15.39 | 142.28 Cr | 0.2691 |
| 2023-09-30 | 410.06 Cr | 210.94 Cr | 199.12 Cr | 0.4856 | 125.64 Cr | 114.87 Cr | 15.06 | 137.40 Cr | 0.2801 |
| 2023-06-30 | 395.32 Cr | 225.05 Cr | 170.27 Cr | 0.4307 | 115.15 Cr | 103.43 Cr | 13.55 | 126.53 Cr | 0.2616 |
| 2023-03-31 | 389.28 Cr | 223.73 Cr | 165.55 Cr | 0.4253 | 112.80 Cr | 102.11 Cr | 13.45 | 123.93 Cr | 0.2623 |
| 2022-12-31 | 372.07 Cr | 209.87 Cr | 162.20 Cr | 0.4359 | 97.94 Cr | 97.48 Cr | 12.75 | 109.37 Cr | 0.2620 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2023-09-30 | 565.91 Cr | 121.49 Cr | 687.40 Cr | 458.98 Cr | 336.71 Cr | 1,668.32 Cr | 545.47 Cr | 2,412.84 Cr | 310.37 Cr |
| 2023-03-31 | 179.93 Cr | 472.72 Cr | 652.65 Cr | 542.58 Cr | 288.22 Cr | 1,554.46 Cr | 533.74 Cr | 2,205.54 Cr | 293.75 Cr |
| 2022-09-30 | 511.78 Cr | 90.19 Cr | 601.97 Cr | 370.80 Cr | 296.07 Cr | 1,544.13 Cr | 330.52 Cr | 2,021.10 Cr | 307.69 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| No quarterly financial cash flow statement data available. | |||||||||
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2016-10-19 | October 19, 16 | 5:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,687.80 | ₹4,049,504,784,000.00 | ₹2,404,272.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,667.00 | ₹1,769,881,823,000.00 | ₹431,430.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,362.50 | ₹1,133,629,620,750.00 | ₹1,419,556.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,252.50 | ₹1,100,792,362,500.00 | ₹412,987.00 |
| Mankind Pharma Limited | MANKIND | ₹2,381.30 | ₹982,693,571,365.00 | ₹192,187.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹974.95 | ₹981,023,938,500.00 | ₹1,046,498.00 |
| Lupin Limited | LUPIN | ₹1,999.60 | ₹913,207,322,000.00 | ₹475,900.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,150.20 | ₹668,038,460,400.00 | ₹1,133,056.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,847.50 | ₹579,591,337,500.00 | ₹382,701.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,669.90 | ₹471,247,449,900.00 | ₹937,744.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹1,004.50 | ₹384,288,559,536.00 | ₹284,738.00 |
| Laurus Labs Limited | LAURUSLABS | ₹666.60 | ₹359,466,049,800.00 | ₹1,292,254.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,368.40 | ₹347,168,553,600.00 | ₹279,721.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,634.20 | ₹329,043,190,400.00 | ₹135,145.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,776.20 | ₹288,595,199,800.00 | ₹1,424,706.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,734.40 | ₹270,521,305,600.00 | ₹148,082.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹10,509.50 | ₹262,737,500,000.00 | ₹106,451.00 |
| Piramal Enterprises Limited | PEL | ₹1,132.60 | ₹256,735,502,800.00 | ₹286,201.00 |
| Eris Lifesciences Limited | ERIS | ₹1,795.10 | ₹244,465,693,500.00 | ₹274,234.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹999.10 | ₹196,386,093,300.00 | ₹47,032.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,094.20 | ₹174,285,270,200.00 | ₹6,466,031.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,193.00 | ₹169,264,870,700.00 | ₹58,120.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹912.70 | ₹163,473,697,000.00 | ₹1,294,720.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,140.30 | ₹162,687,841,510.00 | ₹113,463.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹509.40 | ₹123,551,913,600.00 | ₹1,034,675.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,831.00 | ₹96,791,101,400.00 | ₹9,403.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹985.80 | ₹96,402,269,220.00 | ₹608,474.00 |
| Strides Pharma Science Limited | STAR | ₹882.45 | ₹81,328,974,615.00 | ₹737,669.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹885.65 | ₹80,270,551,203.00 | ₹275,301.00 |
| FDC Limited | FDC | ₹475.85 | ₹77,473,138,500.00 | ₹335,602.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹165.90 | ₹53,838,199,800.00 | ₹784,168.00 |
| Innova Captab Limited | INNOVACAP | ₹907.30 | ₹51,920,178,989.00 | ₹790,854.00 |
| Suven Life Sciences Limited | SUVEN | ₹236.03 | ₹51,472,006,220.00 | ₹2,123,847.00 |
| Sequent Scientific Limited | SEQUENT | ₹197.26 | ₹49,374,572,520.00 | ₹872,716.00 |
| Hikal Limited | HIKAL | ₹375.80 | ₹46,336,515,800.00 | ₹173,076.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹606.10 | ₹42,672,955,380.00 | ₹100,232.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹463.75 | ₹42,326,462,500.00 | ₹202,711.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,341.50 | ₹38,726,068,500.00 | ₹63,054.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹370.65 | ₹37,168,040,700.00 | ₹24,849.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹714.10 | ₹36,218,509,310.00 | ₹99,610.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹64.67 | ₹35,436,185,180.00 | ₹4,993,774.00 |
| Alembic Limited | ALEMBICLTD | ₹115.66 | ₹29,699,406,004.00 | ₹924,689.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹88.75 | ₹26,050,521,250.00 | ₹694,137.00 |
| Indoco Remedies Limited | INDOCO | ₹280.70 | ₹25,893,985,530.00 | ₹64,810.00 |
Key Executives
No executive data available.
FAQs about Caplin Point Laboratories Limited
What is the current market price of the stock?
The current price is ₹1,446.00.
What is the 52-week price range?
The range is ₹180.0-1468.9.
What is the market capitalization of the company?
The market capitalization is ₹10,937.95 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 29.14.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Caplin Point Laboratories Limited (ISIN: INE475E01026) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹10,937.95 crores and an average daily volume of 18,900 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹4.5.